Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor

scientific article published on 22 December 2015

Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/ACSMEDCHEMLETT.5B00425
P932PMC publication ID4716590
P698PubMed publication ID26819676

P50authorCharles JayneQ88797848
P2093author name stringFrancisco Velazquez
Robert Chase
Sathesh Bhat
Sony Agrawal
Srikanth Venkatraman
Hubert Josien
Jin Wu
Murali Rajagopalan
Thomas Bara
Shouwu Miao
Yan Xia
Unmesh Shah
John Howe
Rebecca T Ruck
Patrick Pinto
Samuel Chackalamannil
Yongxin Han
Ian W Davies
Santhosh F Neelamkavil
Stacia Kargman
Donald Sperbeck
Andrew Nolting
Zhuyan Guo
Vincent J Colandrea
Austin Chen
Mark Cartwright
Aileen Soriano
Chad Bennett
Nicole Buist
Keith Eagen
Martin Clasby
Dipshikha Biswas
Duane Burnette
Karen Marcantonio
Linda Brockunier
Mariappan Chelliah
Randy Miller
P2860cites workSofosbuvir, a Significant Paradigm Change in HCV TreatmentQ26781773
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infectionQ27644511
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A proteaseQ27684622
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genomeQ27860719
Diagnosis, management, and treatment of hepatitis C: an updateQ29619682
Telaprevir for previously untreated chronic hepatitis C virus infectionQ29619800
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Boceprevir for untreated chronic HCV genotype 1 infectionQ29620617
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsQ34276394
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with preQ34451707
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 InfectionQ38522622
Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A ProteaseQ39658512
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsQ39782827
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325.Q42155851
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infectionQ42235540
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitorQ42242164
Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution.Q42712427
P433issue1
P304page(s)111-116
P577publication date2015-12-22
P1433published inACS Medicinal Chemistry LettersQ2819061
P1476titleDiscovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor
P478volume7

Reverse relations

cites work (P2860)
Q39151677Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Q53622320Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors.
Q40618808Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182.
Q92126689Targeting HIV/HCV Coinfection Using a Machine Learning-Based Multiple Quantitative Structure-Activity Relationships (Multiple QSAR) Method
Q53755762The utilization of spirocyclic scaffolds in novel drug discovery.

Search more.